Family

Loading Family data...

• 15 United States
• 10 France
• 8 Japan
• 7 China
• 5 Korea
• 2 Other

Patent Owner(s)

Patent Owner	Address
KURARAY CO LTD	1621 SAKAZU KURASHIKI-SHI OKAYAMA 7100801
YAMAGUCHI UNIVERSITY	1677-1 YOSHIDA YAMAGUCHI-SHI YAMAGUCHI 7538511

International Classification(s)

• B32B:LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA....

• 2010 Application Filing Year
• B32B Class
• 4989 Applications Filed
• 2308 Patents Issued To-Date
• 46.27 % Issued To-Date

Inventor(s)

Inventor Name	Address	# of filed Patents	Total Citations
Fujiwara, Naoki	Okayama, JP	189	1698
# of filed Patents : 189 Total Citations : 1698
Higa, Mitsuru	Yamaguchi, JP	9	64
# of filed Patents : 9 Total Citations : 64
Jikihara, Atsushi	Okayama, JP	17	131
# of filed Patents : 17 Total Citations : 131
Kobayashi, Kenichi	Okayama, JP	337	4604
# of filed Patents : 337 Total Citations : 4604

Cited Art Landscape

Load Citation

• No Cited Art to Display

Loading Cited Art Landscape...

Patent Citation Ranking

• 4 Citation Count
• B32B Class

• 6.23 % this patent is cited more than
• 13 Age

Forward Cite Landscape

Load Citation

• No Forward Cites to Display

Loading Forward Cite Landscape...

Maintenance Fees

Fee	Large entity fee	small entity fee	micro entity fee	due date

Fee	Large entity fee	small entity fee	micro entity fee
Surcharge after expiration - Late payment is unavoidable	$700.00	$350.00	$175.00
Surcharge after expiration - Late payment is unintentional	$1,640.00	$820.00	$410.00

Full Text

US Patent No: 7902151

Methods and compositions for modulating immunity

---

Abstract

---

Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of a CD200 protein or a nucleic acid encoding a CD200 protein. The methods are useful in preventing graft rejection, fetal loss, autoimmune disease, and allergies. Methods and compositions for preventing immune suppression are also disclosed. The methods involve administering an effective amount of an agent that inhibits CD200. Such methods are useful in treating cancer.

---

 

---

Description

---

Claims

---

Claims data not available

---

Legal Events

 

• STCH2015
• FP2015
• LAPS2015
• REMI2014
• I2011
• P2009
• F2009
• AS2009
• PD1997

Date	Code	Event	Description
Apr 06, 2015	STCH	INFORMATION ON STATUS: PATENT DISCONTINUATION	free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362
Mar 08, 2015	FP	LAPSED DUE TO FAILURE TO PAY MAINTENANCE FEE	Effective Date: Mar 08, 2015
Mar 08, 2015	LAPS	LAPSE FOR FAILURE TO PAY MAINTENANCE FEES
Oct 17, 2014	REMI	MAINTENANCE FEE REMINDER MAILED
Mar 08, 2011	I	Issuance
Sep 17, 2009	P	Published
May 22, 2009	F	Filing
May 22, 2009	AS	ASSIGNMENT	free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GORCZYNSKI, REGINALD M.;CLARK, DAVID A.;REEL/FRAME:022725/0966;SIGNING DATES FROM 20040819 TO 20040923 Owner name: TRILLIUM THERAPEUTICS INC., CANADA free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GORCZYNSKI, REGINALD M.;CLARK, DAVID A.;SIGNING DATES FROM 20040819 TO 20040923;REEL/FRAME:022725/0966 Owner name: TRILLIUM THERAPEUTICS INC., CANADA
Nov 07, 1997	PD	Priority Date